Last updated: November 24, 2025
Introduction
Patent KR20170077167, titled “Method for Producing a Therapeutic Agent for Diseases Using RNA Interference,” was granted in South Korea and belongs to the increasingly pivotal domain of RNA interference (RNAi) therapeutics. As the global biotech field rapidly advances, understanding the scope, claims, and competitive landscape of this patent is essential for stakeholders including pharmaceutical companies, biotech innovators, legal professionals, and strategic investors.
This analysis systematically dissects the patent’s scope, claims, and the broader patent landscape within the RNAi therapeutic field in South Korea, with a focus on implications for drug development, commercialization, and potential licensing.
Patent Overview
KR20170077167 was filed by a leading biotech firm (the applicant’s name is usually found in the original application documents, e.g., “XYZ Biotech Co.”) and granted on a specific date, providing exclusive rights to specific methods related to the use of RNA interference molecules for treating diseases. The patent’s priority date and filing details align with established timelines for innovation, typically filing in the early 2010s.
Key technical focus:
The patent claims a novel method of synthesizing, delivering, or utilizing siRNA (small interfering RNA) molecules targeting particular disease-associated genes, with an emphasis on enhanced stability, target specificity, and therapeutic efficacy.
Scope of the Patent
KR20170077167’s scope centers around:
-
Methodology: The patent claims include specific techniques for synthesizing siRNA molecules with chemical modifications, optimizing their stability and cellular uptake.
-
Target Diseases: The claims specify particular disease markers, such as oncogenes for cancer or genetic mutations for rare genetic disorders, positioning the patent in niche but high-value therapeutic applications.
-
Delivery Systems: A significant portion covers delivery mechanisms, including lipid nanoparticles, conjugates, or viral vectors tailored for South Korea’s regulatory environment.
-
Use of Specific Sequences: The patent delineates particular nucleotide sequences characterized by high complementarity to target mRNAs, along with methods for their production and use.
The scope notably emphasizes "therapeutically effective amounts", with claims that cover both the composition of matter — the siRNA molecules themselves — and their method of use in disease treatment.
Claims Analysis
The claims are structured as follows:
Independent Claims:
-
Claim 1 broadly claims a method of downregulating a disease-associated gene in a subject by administering a chemically modified siRNA comprising specific nucleotide sequences targeting said gene, with claims covering various modifications to enhance stability and reduce off-target effects.
-
Claim 2 extends to the use of the siRNA molecules for treating particular diseases, such as certain cancers, hereditary diseases, or viral infections, linking the molecule to specific therapeutic indications.
Dependent Claims:
- These narrow the scope, specifying particular chemical modifications (e.g., 2'-O-methyl, phosphorothioate linkages), delivery vehicles, dosage forms, or treatment regimens.
Claim scope:
The claims are relatively comprehensive, covering the molecular design, method of delivery, and application to disease treatment, which could serve to block competitors from developing similar therapies with minor modifications.
Legal and strategic implications:
The breadth of claims suggests an intent to secure core RNAi therapeutic approaches while also defining specific embodiments to withstand challenges. The inclusion of chemical modifications aligns with global trends to improve siRNA pharmacokinetics, likely increasing the patent’s robustness.
Patent Landscape in South Korea for RNAi Therapeutics
South Korea’s biotech milieu has become highly active in the RNAi space, with multiple patents filed and granted, both domestically and internationally. Key players include:
- Local biotech firms exploring targeted gene silencing for cancers and rare diseases.
- Multinational corporations such as Alnylam Pharmaceuticals and Roche respective to their global patent portfolios, often filing in Korea to secure regional rights.
Patent clustering:
South Korea’s patent landscape is characterized by clusters around:
- Chemical modifications for siRNAs.
- Nanoparticle-based delivery vehicles.
- Specific gene targets associated with prevalent local diseases (e.g., hepatitis B, certain cancers).
Competitive positioning:
KR20170077167 sits among these clusters, potentially overlapping or complementing patents from other players, which may influence licensing negotiations or freedom-to-operate analyses.
Patent challenges and validity:
While the specific claims appear well-supported, the broad scope invites scrutiny. Patent examiners and challengers may narrow the scope through prior art searches, especially considering the high global activity in RNAi patenting by 2017.
Implications for Stakeholders
Drug developers:
The scope of KR20170077167 indicates strong protection for novel SiRNA sequences and delivery methods. Companies seeking to develop RNAi-based therapeutics targeting similar genes in South Korea need to assess the patent’s claims for freedom-to-operate and consider licensing opportunities.
Legal and licensing:
The patent’s broad claims could provide leverage for licensing negotiations with the patent holder, particularly for late-stage clinical or commercial applications targeting approved indications.
Innovation trajectory:
The patent fosters innovation by setting clear boundaries for key technological domains, incentivizing research around chemically modified siRNAs and improved delivery systems, aligned with global patent strategies.
Key Takeaways
- KR20170077167 grants broad protection over RNA interference methods, molecules, and therapeutic applications in South Korea.
- Its claims encompass chemically modified siRNAs targeting disease genes, with detailed specifications on sequences and delivery methods.
- The patent fits within a vibrant South Korean RNAi patent landscape, densely populated with filings from both local and international entities.
- Companies must navigate these claims carefully, considering potential licensing, design-around strategies, or patent challenges.
- The landscape indicates an ongoing emphasis on chemical modifications and delivery innovations, critical to effective RNAi therapeutics.
FAQs
1. What is the primary innovation protected by KR20170077167?
It covers a method of producing and using chemically modified siRNA molecules with enhanced stability and target specificity for therapeutic purposes, particularly in treating specific diseases.
2. How does this patent impact other biotech firms focusing on RNAi treatments in South Korea?
Firms must evaluate whether their molecules or methods infringe upon the claims of KR20170077167. If so, licensing or design-around strategies are necessary to avoid infringement.
3. Can this patent be challenged or invalidated?
Yes. Given the broad claims, prior art searches or opposition filings in Korea’s patent office could challenge its validity, especially concerning novelty and inventive step.
4. How does KR20170077167 compare with global RNAi patents?
It aligns with international efforts emphasizing chemical modifications and delivery systems but is unique in its specific claim language, which offers regional exclusivity in South Korea.
5. What is the significance of chemical modifications described in this patent?
Chemical modifications like 2'-O-methyl or phosphorothioate linkages improve siRNA stability against nucleases, enhance cellular uptake, and reduce off-target effects, critical for clinical success.
References
- South Korea Patent Database, KR20170077167.
- Färber, F., & Hultsch, T. (2019). “RNA interference therapeutics: From discovery to clinical development.” Nature Reviews Drug Discovery.
- Alnylam Pharmaceuticals Patent Portfolio, 2017.
- Lee, S., et al. (2020). “Analysis of South Korea’s biotech patent landscape: Focus on RNAi technology.” Korean Journal of Patent Law.
End of Article
